AstraZeneca Annual Report and Group Financial Record US GAAP 126 Form 20-F Information 2003 Group Financial Record US GAAP Group Financial Record US GAAP The selected financial data set out below for each of the years in the five year period ended 31 December 2003, has been extracted or derived from audited Financial Statements.
The selected financial data should be read in conjunction with, and are qualified in their entirety by reference to, the Financial Statements of AstraZeneca and the notes thereto, which are included elsewhere in this document.
Consolidated income statement data For the years ended 31 December 1999 2000 2001 2002 2003 Net income loss from operations $m 3,539 865 1,397 2,307 2,268 Net income loss from operations per Ordinary Share $2.26 $0.49 $0.79 $1.33 $1.33 Diluted income loss from operations per Ordinary Share $2.26 $0.49 $0.79 $1.33 $1.33 Net income loss from operations had SFAS No.
142 been adopted 2,833 1,716 2,125 Net and diluted income loss per Ordinary Share from operations had SFAS No.
142 been adopted $1.81 $0.97 $1.21 Ratio of earnings to fixed charges For the Group with estimated material adjustments to accord with US GAAP 19.3 15.5 25.0 36.7 78.9 Consolidated balance sheet data At 31 December 1999 2000 2001 2002 2003 $m $m $m $m $m Total assets 46,640 41,500 38,081 42,578 45,378 Shareholders equity 33,735 29,707 27,402 30,183 33,654 Merger accounting For the purpose of US GAAP, the merger has been regarded as a purchase accounting acquisition of Astra by Zeneca.
Ratio of earnings to fixed charges UK and US GAAP For the purpose of computing these ratios, earnings consist of the income from continuing ordinary activities before taxation of Group companies and income received from companies owned 50% or less, plus fixed charges excluding capitalised interest.
Fixed charges consist of interest including capitalised interest on all indebtedness, amortisation of debt discount and expense and that portion of rental expense representative of the interest factor.
The comparative figures have been restated from those previously disclosed to reflect the reclassification of the operations of Specialties and Agrochemicals as discontinued.
